Diametric Capital LP Has $860,000 Stock Position in Amedisys, Inc. (NASDAQ:AMED)

Diametric Capital LP increased its stake in Amedisys, Inc. (NASDAQ:AMED) by 26.3% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 9,476 shares of the health services provider’s stock after purchasing an additional 1,976 shares during the quarter. Diametric Capital LP’s holdings in Amedisys were worth $860,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Blue Trust Inc. lifted its stake in Amedisys by 55.1% in the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock valued at $34,000 after acquiring an additional 124 shares during the last quarter. HBW Advisory Services LLC acquired a new stake in Amedisys in the 4th quarter valued at about $38,000. Versant Capital Management Inc grew its holdings in Amedisys by 68.5% during the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock worth $41,000 after purchasing an additional 183 shares during the period. Vestcor Inc acquired a new position in Amedisys during the fourth quarter worth approximately $73,000. Finally, Venturi Wealth Management LLC raised its stake in Amedisys by 397.4% in the fourth quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider’s stock valued at $89,000 after buying an additional 779 shares during the period. 94.36% of the stock is owned by institutional investors.

Amedisys Stock Down 0.1 %

Shares of AMED opened at $92.63 on Tuesday. The firm has a market cap of $3.04 billion, a P/E ratio of 36.76, a price-to-earnings-growth ratio of 1.78 and a beta of 0.76. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. Amedisys, Inc. has a 52 week low of $82.15 and a 52 week high of $98.95. The firm’s 50-day simple moving average is $92.29 and its 200 day simple moving average is $92.37.

Amedisys (NASDAQ:AMED) last posted its earnings results on Wednesday, February 26th. The health services provider reported $0.96 EPS for the quarter, missing the consensus estimate of $1.05 by ($0.09). The firm had revenue of $598.05 million during the quarter, compared to analyst estimates of $602.38 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. On average, analysts forecast that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Stephens reiterated an “equal weight” rating and set a $101.00 target price on shares of Amedisys in a research note on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $101.00.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.